Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2023 | 2899 | 1.450 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 475 | 1.080 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 322 | 0.750 |
Why?
|
| Organ Transplantation | 1 | 2023 | 204 | 0.730 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 20 | 0.730 |
Why?
|
| Cancer Survivors | 5 | 2022 | 741 | 0.700 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 255 | 0.680 |
Why?
|
| Obesity | 4 | 2020 | 2939 | 0.660 |
Why?
|
| Lymphoma | 2 | 2023 | 1514 | 0.600 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 247 | 0.570 |
Why?
|
| Overweight | 2 | 2020 | 484 | 0.570 |
Why?
|
| Genetic Markers | 3 | 2015 | 1015 | 0.530 |
Why?
|
| Survivors | 6 | 2020 | 1024 | 0.510 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 4326 | 0.510 |
Why?
|
| Folic Acid | 3 | 2013 | 368 | 0.490 |
Why?
|
| Body Mass Index | 3 | 2020 | 2236 | 0.470 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 382 | 0.470 |
Why?
|
| Conscious Sedation | 1 | 2012 | 105 | 0.370 |
Why?
|
| Child | 29 | 2023 | 30343 | 0.370 |
Why?
|
| Hematology | 1 | 2012 | 99 | 0.360 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 337 | 0.330 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 1522 | 0.320 |
Why?
|
| Membrane Proteins | 2 | 2015 | 2958 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 606 | 0.280 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 908 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2015 | 5436 | 0.280 |
Why?
|
| Genotype | 5 | 2017 | 4111 | 0.280 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 1060 | 0.270 |
Why?
|
| Risk Factors | 11 | 2023 | 17814 | 0.270 |
Why?
|
| Cognition Disorders | 2 | 2011 | 772 | 0.270 |
Why?
|
| Postoperative Complications | 1 | 2020 | 5679 | 0.250 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 1442 | 0.240 |
Why?
|
| Neoplasms | 7 | 2022 | 15852 | 0.240 |
Why?
|
| Quality Improvement | 1 | 2012 | 916 | 0.240 |
Why?
|
| Child, Preschool | 17 | 2021 | 16919 | 0.230 |
Why?
|
| Pediatrics | 2 | 2019 | 1178 | 0.230 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2013 | 26 | 0.210 |
Why?
|
| Methotrexate | 2 | 2023 | 1026 | 0.200 |
Why?
|
| Liver Transplantation | 1 | 2011 | 1184 | 0.200 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.190 |
Why?
|
| Pharyngitis | 1 | 2021 | 47 | 0.190 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 102 | 0.190 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 87 | 0.190 |
Why?
|
| Humans | 34 | 2023 | 270825 | 0.170 |
Why?
|
| DNA Methylation | 2 | 2020 | 2743 | 0.170 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 24 | 0.160 |
Why?
|
| Adiposity | 1 | 2020 | 238 | 0.160 |
Why?
|
| Male | 22 | 2021 | 128398 | 0.160 |
Why?
|
| Francisella | 1 | 2017 | 4 | 0.150 |
Why?
|
| Tularemia | 1 | 2017 | 15 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 161 | 0.150 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 2083 | 0.150 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 388 | 0.150 |
Why?
|
| Mycoses | 1 | 2021 | 396 | 0.150 |
Why?
|
| Attention | 1 | 2019 | 285 | 0.150 |
Why?
|
| Age Factors | 3 | 2021 | 5485 | 0.140 |
Why?
|
| Infant | 8 | 2021 | 13867 | 0.140 |
Why?
|
| Adolescent | 14 | 2021 | 32508 | 0.130 |
Why?
|
| Weight Gain | 1 | 2019 | 475 | 0.130 |
Why?
|
| Female | 22 | 2021 | 148456 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 254 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2015 | 62 | 0.120 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 11 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2015 | 140 | 0.120 |
Why?
|
| Retrospective Studies | 7 | 2023 | 39679 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 2198 | 0.110 |
Why?
|
| Health Services | 1 | 2014 | 101 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1076 | 0.110 |
Why?
|
| Birth Weight | 1 | 2015 | 350 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1068 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2015 | 6025 | 0.110 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 148 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1596 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 603 | 0.100 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 331 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1735 | 0.100 |
Why?
|
| Gestational Age | 1 | 2015 | 1145 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1212 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2014 | 1079 | 0.090 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1043 | 0.090 |
Why?
|
| Premature Birth | 1 | 2015 | 403 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 350 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 2359 | 0.090 |
Why?
|
| Texas | 1 | 2021 | 6411 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 315 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1955 | 0.080 |
Why?
|
| Young Adult | 4 | 2021 | 22035 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 14679 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 4495 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 4980 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 243 | 0.080 |
Why?
|
| Prevalence | 1 | 2016 | 3409 | 0.080 |
Why?
|
| Algorithms | 2 | 2021 | 3905 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2017 | 8566 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 2022 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 2 | 2022 | 954 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 1259 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1038 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3067 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7782 | 0.070 |
Why?
|
| Adult | 6 | 2020 | 81540 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 935 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2020 | 13361 | 0.060 |
Why?
|
| Hospitalization | 1 | 2014 | 2192 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 1065 | 0.060 |
Why?
|
| Switzerland | 1 | 2023 | 25 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 1486 | 0.060 |
Why?
|
| Pregnancy | 1 | 2015 | 8034 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 2280 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2421 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2023 | 296 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 6983 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 545 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 449 | 0.040 |
Why?
|
| Headache | 1 | 2021 | 174 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 1061 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2008 | 1462 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 269 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 356 | 0.040 |
Why?
|
| Recurrence | 2 | 2019 | 4882 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2011 | 6828 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 685 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 273 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2020 | 360 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 239 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 33821 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 515 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 2286 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2017 | 168 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 2017 | 271 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2017 | 211 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2017 | 233 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 360 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1089 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 10698 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 604 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 3073 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1069 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2021 | 876 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 10350 | 0.030 |
Why?
|
| Hospital Records | 1 | 2014 | 10 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1173 | 0.030 |
Why?
|
| Monosomy | 1 | 2015 | 98 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 329 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 3033 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1669 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 684 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 464 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 1187 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2014 | 575 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 16598 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1730 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 2561 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4329 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2017 | 2089 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 566 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 2312 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 13977 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 753 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 13103 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 2507 | 0.020 |
Why?
|
| Apoptosis | 1 | 2022 | 7853 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1338 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2010 | 339 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 3645 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 3544 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3349 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 2029 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 520 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 7810 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6464 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2010 | 1858 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 9430 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 1553 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 15239 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 6185 | 0.010 |
Why?
|
| United States | 1 | 2014 | 15962 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 22452 | 0.010 |
Why?
|